Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis.

Thiruvengadam SS, O╩╝Malley M, LaGuardia L, Lopez R, Wang Z, Shadrach BL, Chen Y, Li C, Veigl ML, Barnholtz-Sloan JS, Pai RK, Church JM, Kalady MF, Walsh RM, Burke CA.

Clin Transl Gastroenterol. 2019 Jun 18. doi: 10.14309/ctg.0000000000000053. [Epub ahead of print]

PMID:
31211760
2.

A nonrandomized trial of vitamin D supplementation for Barrett's esophagus.

Cummings LC, Thota PN, Willis JE, Chen Y, Cooper GS, Furey N, Bednarchik B, Alashkar BM, Dumot J, Faulx AL, Fink SP, Kresak AM, Abusneineh B, Barnholtz-Sloan J, Leahy P, Veigl ML, Chak A, Markowitz SD.

PLoS One. 2017 Sep 18;12(9):e0184928. doi: 10.1371/journal.pone.0184928. eCollection 2017.

3.

A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease.

Gittleman HR, Merkulova A, Alhalabi O, Stavrou EX, Veigl ML, Barnholtz-Sloan JS, Schmaier AH.

Front Med (Lausanne). 2016 Apr 29;3:17. doi: 10.3389/fmed.2016.00017. eCollection 2016.

4.

Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2853. doi: 10.1073/pnas.1505059112. Epub 2015 May 4. No abstract available.

5.

Novel recurrently mutated genes in African American colon cancers.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1149-54. doi: 10.1073/pnas.1417064112. Epub 2015 Jan 12.

6.

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.

Thompson CL, Fink SP, Lutterbaugh JD, Elston RC, Veigl ML, Markowitz SD, Li L.

PLoS One. 2013 May 22;8(5):e64122. doi: 10.1371/journal.pone.0064122. Print 2013.

7.

Global mutational profiling of formalin-fixed human colon cancers from a pathology archive.

Adams MD, Veigl ML, Wang Z, Molyneux N, Sun S, Guda K, Yu X, Markowitz SD, Willis J.

Mod Pathol. 2012 Dec;25(12):1599-608. doi: 10.1038/modpathol.2012.121. Epub 2012 Aug 10.

8.

A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage.

Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA.

Oncogene. 2003 Oct 20;22(47):7376-88. Review.

PMID:
14576845
9.

Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation.

Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA, Radivoyevitch T, Veigl ML, Laughlin MJ.

Blood. 2003 Dec 15;102(13):4608-17. Epub 2003 Aug 28.

10.

Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.

Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ.

Cancer Res. 2001 Nov 15;61(22):8290-7.

11.

Mismatch repair and drug responses in cancer.

Sedwick WD, Markowitz SD, Veigl ML.

Drug Resist Updat. 1999 Oct;2(5):295-306.

PMID:
11504504
12.

Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability.

Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz SD, Sedwick WD.

Oncogene. 2000 Apr 27;19(18):2249-56.

13.

Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells.

Chen WD, Eshleman JR, Aminoshariae MR, Ma AH, Veloso N, Markowitz SD, Sedwick WD, Veigl ML.

J Natl Cancer Inst. 2000 Mar 15;92(6):480-5.

PMID:
10716966
14.

Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.

Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, Willson JK, Schwartz S, Markowitz SD.

Oncogene. 1998 Aug 13;17(6):719-25.

15.

Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702.

16.

Increased transversions in a novel mutator colon cancer cell line.

Eshleman JR, Donover PS, Littman SJ, Swinler SE, Li GM, Lutterbaugh JD, Willson JK, Modrich P, Sedwick WD, Markowitz SD, Veigl ML.

Oncogene. 1998 Mar 5;16(9):1125-30.

17.

Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability.

Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD.

Oncogene. 1996 Apr 4;12(7):1425-32.

PMID:
8622858
18.

Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.

Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, Veigl ML, Sedwick WD, Markowitz SD.

Oncogene. 1995 Jan 5;10(1):33-7.

PMID:
7824277
19.
20.

Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.

Sedwick WD, Anderson RD, Baxter J, Donover S, Schneiter S, Veigl ML.

Mutat Res. 1995 Jan;326(1):17-27.

PMID:
7528882
21.

Excision repair reduces doxorubicin-induced genotoxicity.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Mutat Res. 1993 Oct;294(3):215-22.

PMID:
7692261
22.

Sequencing of double-stranded polymerase chain reaction products for mutation analysis.

Anderson RD, Bao CY, Minnick DT, Baxter J, Veigl ML, Sedwick WD.

Mutat Res. 1993 Jul;288(1):181-5.

PMID:
7686261
23.
24.

Mutational specificity of 1,3-bis-(2-chloroethyl)-1-nitrosourea in a Chinese hamster ovary cell line.

Minnick DT, Veigl ML, Sedwick WD.

Cancer Res. 1992 Sep 1;52(17):4688-95.

25.

DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Cancer Res. 1991 Aug 1;51(15):3930-7.

26.

Specificities mediated by neighboring nucleotides appear to underlie mutation induced by antifolates in E. coli.

Veigl ML, Schneiter S, Mollis S, Sedwick WD.

Mutat Res. 1991 Jan;246(1):75-91.

PMID:
1986269
27.

Rapid mapping of deletion and duplication mutations by the polymerase chain reaction.

Anderson RD, Veigl ML, Sedwick WD.

Biochem Biophys Res Commun. 1990 Jul 31;170(2):416-20. No abstract available.

PMID:
2200400
28.

The uses and limitations of calmodulin antagonists.

Veigl ML, Klevit RE, Sedwick WD.

Pharmacol Ther. 1989;44(2):181-239. Review. No abstract available.

PMID:
2519344
29.

DNA base modification: ionized base pairs and mutagenesis.

Sowers LC, Shaw BR, Veigl ML, Sedwick WD.

Mutat Res. 1987 Apr;177(2):201-18.

PMID:
3561423
30.

Induction of myeloid differentiation of HL-60 cells with naphthalene sulfonamide calmodulin antagonists.

Veigl ML, Sedwick WD, Niedel J, Branch ME.

Cancer Res. 1986 May;46(5):2300-5.

31.

Differences in calmodulin levels of normal and transformed cells as determined by culture conditions.

Veigl ML, Vanaman TC, Branch ME, Sedwick WD.

Cancer Res. 1984 Aug;44(8):3184-9.

32.

Calcium and calmodulin in cell growth and transformation.

Veigl ML, Vanaman TC, Sedwick WD.

Biochim Biophys Acta. 1984;738(1-2):21-48. Review. No abstract available.

PMID:
6331500
33.

Calmodulin and Ca2+ in normal and transformed cells.

Veigl ML, Sedwick WD, Vanaman TC.

Fed Proc. 1982 May;41(7):2283-8.

PMID:
6281082
34.

Investigation of calmodulin-regulated NAD kinase in proliferating fibroblasts.

Veigl ML, Vanaman TC.

Ann N Y Acad Sci. 1980;356:439-50. No abstract available.

PMID:
6263162

Supplemental Content

Loading ...
Support Center